<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489227</url>
  </required_header>
  <id_info>
    <org_study_id>CHS-1420-02</org_study_id>
    <nct_id>NCT02489227</nct_id>
  </id_info>
  <brief_title>Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis</brief_title>
  <acronym>PsOsim</acronym>
  <official_title>A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coherus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coherus Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque
      psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 55-week, randomized, double-blind, active-control, parallel group, multicenter,
      global study in subjects with active, moderate to severe, chronic PsO.

      The study will consist of 24 weeks of administration of blinded study drug, divided into
      Treatment Period 1 and Treatment Period 2, then 23 weeks of administration of open-label
      CHS-1420 and a Follow-up visit 8 weeks after the last dose. Subjects who meet
      inclusion/exclusion criteria will be stratified by body mass index (BMI), and age and
      randomized 1:1 to receive CHS-1420 or Humira in Treatment Period 1. Subjects assigned to
      CHS-1420 will continue to receive CHS-1420 in Period 2. Subjects assigned to Humira in Period
      1 will be randomly assigned (1:1) to either continue with Humira in Treatment Period 2 or to
      switch to CHS-1420 in Treatment Period 2. All subjects will receive open label CHS-1420 in
      Treatment Period 3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">May 6, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The efficacy success criterion was the equivalence between CHS-1420 and Humira at Week 12. Equivalence was based upon 2-sided 95% confidence interval (CI) for the difference between the proportions of subjects in the CHS-1420 and Humira groups achieving PASI-75 at Week 12. If the 95% CI lay entirely within the interval (-15%, 15%), equivalence was established.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">545</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Humira (adalimumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be assigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. The assignments for treatment sequences (Treatment Period 1 and Treatment Period 2) were made randomly at the beginning of Treatment Period 1. At week 24 subjects will switch to CHS-1420 open label until study end.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHS-1420</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHS-1420</intervention_name>
    <arm_group_label>CHS-1420</arm_group_label>
    <arm_group_label>Humira (adalimumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>Humira (adalimumab)</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults

          -  PsO diagnosis for 6 months

          -  Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment
             (PSGA) score greater than or equal to 3 (based on a scale of 0-5),

          -  Body Surface Area (BSA) involved with PsO greater than or equal to 10%

        Exclusion Criteria:

          -  Forms of psoriasis other than PsO

          -  Drug induced psoriasis

          -  Positive QuantiFERON-tuberculosis (TB) Gold Test

          -  Presence of significant comorbid conditions

          -  Chemistry and hematology values outside protocol specified range

          -  Major systemic infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara P Finck, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Coherus Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sadra Sasha Jazayeri, MD</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encino Research Center</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology and Laser Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenneth M Stein, MD</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthCare Partners Medical Group Clinical Research Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research Center, LLC.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Research Associates LLC</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Francisco A Kerdel, MD</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linda Tripodis Murray, DO</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACRC-Dermatology</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark A Knautz, MD</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Institute</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jack C Scott, MD</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Craig L Leonardi, MD</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Arthritis &amp; Rheumetology of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Joseph Noss, MD</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology and Skin Surgery Center, PC</name>
      <address>
        <city>Exton</city>
        <state>Pennsylvania</state>
        <zip>19341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Henry Kopp, MD</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol, LLC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Research Center, Inc.</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies TMC/ Museum District Office</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology and Venerology Diseases, EOOD, Sofia City</name>
      <address>
        <city>Sofia</city>
        <zip>1415</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingsway Clinical Research</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M8X 1Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research by ICLS</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Probity Medical Research, Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Dermacross SA</name>
      <address>
        <city>Santiago</city>
        <zip>7640881</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Intrnacional de Estudios Clinicos- CIEC</name>
      <address>
        <city>Santiago</city>
        <zip>8420383</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonio Guglielmetti, MD</name>
      <address>
        <city>Viña Del Mar</city>
        <zip>2520000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naftalan, Special Hospital for Medical Rehabilitation</name>
      <address>
        <city>Ivanić-Grad</city>
        <zip>10310</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre &quot;Osijek&quot;</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital, Dermatology Clinic</name>
      <address>
        <city>Raja</city>
        <state>Tartu</state>
        <zip>50417</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innomedica OÜ</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Estonian Medical Centre Foundation Skin and Sexual Diseases Center</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aleksandre Aladshvili Clinic LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tbilisi State Medical University Alexandre Aladashvili University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific/Research National Center of Dermatology and Venereology</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Institute LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Clto Ltd</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology- Ha'Emek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center Dermatologic Clinic</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center Department of Dermatology</name>
      <address>
        <city>Petah tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology Phototherapy and Day Care Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Clinical and Molecular Sciences Dermatologic Clinic</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine and Medical Specialties Unit of Dermatology</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Clinica Dermosifilopatica Univeristà Cattolica del S.Cuore</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janis Kisis, MD</name>
      <address>
        <city>Jurmala</city>
        <zip>LV-2008</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga 1st Hospital Skin and Sexually Transmitted Diseases Clinical Centre</name>
      <address>
        <city>Riga</city>
        <zip>LV-1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kristine Berzina, MD, PhD</name>
      <address>
        <city>Riga</city>
        <zip>LV-1046</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMSI Institute of Cardiology</name>
      <address>
        <city>Chisinau</city>
        <zip>MD2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zdrowie Osteo-Medic s.c.</name>
      <address>
        <city>Białystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Badurski i wspólnicy Spółka Jawna</name>
      <address>
        <city>Białystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Kliniccznych</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-456</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grażyna Pulka Specjalistyczny Ośrodek, &quot;ALL-MED&quot;</name>
      <address>
        <city>Krakow</city>
        <zip>31-023</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CenterMed Kraków Śp. z o. o.</name>
      <address>
        <city>Kraków</city>
        <zip>31-530</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o. o. Oddzial w Poznaniu</name>
      <address>
        <city>Poznań</city>
        <zip>60-702</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowtnej &quot;NASZ LEKARZ&quot;</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Śp. z o.o.</name>
      <address>
        <city>Warsaw</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny we Wrocławiu, Oddział Dermatologiczny</name>
      <address>
        <city>Wrocław</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altay State Medical University</name>
      <address>
        <city>Barnaul</city>
        <zip>651045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Scientific and Practical Center of Dermatovenereology and Cosmetology of the Public Health Department of Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>109044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State University and Dentistry named after Evdokimov</name>
      <address>
        <city>Moscow</city>
        <zip>121614</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imc &quot;Sogaz&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olga Mikerina, MD</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Biomedical Group</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>94356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Skin and Venereal Diseases of the Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DOST - Dermatovenerologicke oddelenie sanatorneho typu</name>
      <address>
        <city>Svidník</city>
        <zip>089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panorama Medical Centre, Room 136</name>
      <address>
        <city>Panorama</city>
        <state>Cape Town</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicross Pretoria West 1st Floor</name>
      <address>
        <city>Pretoria West</city>
        <state>Pretoria</state>
        <zip>0183</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zubar Fazal Ahmed Vawda. MD</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Park, Room 201, 2nd Floor</name>
      <address>
        <city>Pinelands</city>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synopsis Research cc</name>
      <address>
        <city>Rondebosch</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Heiderberg Clinical Research Centre</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Projects Research SA (PTY) Ltd.</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Private Enterprise &quot;Dzerkalo&quot;</name>
      <address>
        <city>Dnipropetrovs'k</city>
        <zip>49044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk National Medical Univeristy, Dept. of Dermatology and Venereology based on Ivano-Frankivsk Regional Clinical Dermatology and Venereology Dispensary</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution &quot;Kharkiv City Dermatovenereological Dispensary #2</name>
      <address>
        <city>Kharkiv</city>
        <zip>61038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khmel'nytskyy Regional Dermatovenereological Dispensary</name>
      <address>
        <city>Khmel'nyts'kyy</city>
        <zip>29009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical University named after O.O.Bohomolets, Dept. of Dermatology and Venereology based on Oleksandrivska Clinical Hospital of Kyiv City, Dept. of Dermatology</name>
      <address>
        <city>Kyiv</city>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical University named after Danyla Galytskoho, Dept. of Family Medicine and Dermatology, Venereology based on Dept. of Dermatovenereology of the clinical Hospital of Ukrainian State Border Guard Services</name>
      <address>
        <city>Lviv</city>
        <zip>79014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odesa National Medical University, Department of Dermatic and Venereologic Diseases based on Odesa Regional Dermatovenereological Dispensary</name>
      <address>
        <city>Odesa</city>
        <zip>65006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Rivne Regional Dermatology and Venereology Dispensary&quot; of Rivne Regional Council</name>
      <address>
        <city>Rivne</city>
        <zip>33028</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution of Ternopil Regional Council Ternopil Regional Clinical Dermatovenereological Dispensary</name>
      <address>
        <city>Ternopil'</city>
        <zip>46006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Treatment Dermatology and Gynecology Center</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Zaporizhzhya Regional Dermatology and Venereology Clinical Dispensary&quot; of Zaporizhzhya Regional Council</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69063</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 1, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <results_first_submitted>July 3, 2019</results_first_submitted>
  <results_first_submitted_qc>September 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2019</results_first_posted>
  <disposition_first_submitted>May 31, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>June 9, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 14, 2017</disposition_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PsO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 16, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02489227/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CHS-1420</title>
          <description>CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
CHS-1420</description>
        </group>
        <group group_id="P2">
          <title>Humira (Adalimumab) Reassigned to CHS-1420</title>
          <description>Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be reassigned (1:1) to CHS-1420 40mg dose every 2 weeks for weeks 17-23. At week 24 subjects will switch to CHS-1420, 1 dose 40mg every 2 weeks, open label until study end.open label until study end.
Adalimumab
CHS-1420</description>
        </group>
        <group group_id="P3">
          <title>Humira (Adalimumab)</title>
          <description>Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be reassigned (1:1) to continue adalimumab treatment, 1 dose 40mg every 2 weeks for weeks 17-23. At week 24 subjects will switch to CHS-1420, 1 dose 40mg every 2 weeks, open label until study end..
Adalimumab
CHS-1420</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="135"/>
                <participants group_id="P3" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CHS-1420</title>
          <description>CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
CHS-1420</description>
        </group>
        <group group_id="B2">
          <title>Humira (Adalimumab) Reassigned to CHS-1420</title>
          <description>Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be reassigned (1:1) to CHS-1420 40mg dose every 2 weeks for weeks 17-23. At week 24 subjects will switch to CHS-1420, 1 dose 40mg every 2 weeks, open label until study end.
Adalimumab
CHS-1420</description>
        </group>
        <group group_id="B3">
          <title>Humira (Adalimumab)</title>
          <description>Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be reassigned (1:1) to continue adalimumab treatment, 1 dose 40mg every 2 weeks for weeks 17-23. At week 24 subjects will switch to CHS-1420, 1 dose 40mg every 2 weeks, open label until study end.
Adalimumab
CHS-1420</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="274"/>
            <count group_id="B2" value="135"/>
            <count group_id="B3" value="136"/>
            <count group_id="B4" value="545"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="127"/>
                    <measurement group_id="B4" value="507"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12</title>
        <description>The efficacy success criterion was the equivalence between CHS-1420 and Humira at Week 12. Equivalence was based upon 2-sided 95% confidence interval (CI) for the difference between the proportions of subjects in the CHS-1420 and Humira groups achieving PASI-75 at Week 12. If the 95% CI lay entirely within the interval (-15%, 15%), equivalence was established.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Humira (Adalimumab)</title>
            <description>Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be reassigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. At week 24 subjects will switch to CHS-1420 open label until study end.
CHS-1420
Adalimumab</description>
          </group>
          <group group_id="O2">
            <title>CHS-1420</title>
            <description>CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
CHS-1420</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12</title>
          <description>The efficacy success criterion was the equivalence between CHS-1420 and Humira at Week 12. Equivalence was based upon 2-sided 95% confidence interval (CI) for the difference between the proportions of subjects in the CHS-1420 and Humira groups achieving PASI-75 at Week 12. If the 95% CI lay entirely within the interval (-15%, 15%), equivalence was established.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment Period 1: CHS-1420</title>
          <description>CHS-1420 40mg, 2 doses at Week 0/Day 0 then 40 mg, 1 dose every 2 weeks starting at Week 1 until Week 15</description>
        </group>
        <group group_id="E2">
          <title>Treatment Period 1: Humira (Adalimumab)</title>
          <description>Adalimumab (Humira) 40mg, 2 doses at Week 0/Day 0 then 40 mg, 1 dose every 2 weeks starting at Week 1 until Week 15.</description>
        </group>
        <group group_id="E3">
          <title>Treatment Period 2: CHS-1420/CHS-1420</title>
          <description>At week 16 subjects initially randomized to CHS-1420 will continue CHS-1420 treatment 40 mg, 1 dose every 2 weeks starting at Week 16 to Week 24</description>
        </group>
        <group group_id="E4">
          <title>Treatment Period 2: Humira/CHS-1420</title>
          <description>At Week 16 subjects initially randomized to Humira (adalimumab) will be reassigned to CHS-1420 treatment 40 mg, 1 dose every 2 weeks starting at Week 16 to Week 24</description>
        </group>
        <group group_id="E5">
          <title>Teatment Period 2: Humira/Humira</title>
          <description>At Week 16 subjects initially randomized to Humira (adalimumab) will continue adalimumab treatment 40 mg, 1 dose every 2 weeks starting at Week 16 to Week 24</description>
        </group>
        <group group_id="E6">
          <title>Treatment Period 3: Open Label CHS-1420 Extension</title>
          <description>At week 24 all subjects will switch to CHS-1420 treatment 40 mg, 1 dose every 2 weeks, open label, starting at week 24 until study end</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="271"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital Cystic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic and obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="271"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="274"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="274"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="271"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="474"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara K. Finck, MD</name_or_title>
      <organization>Coherus BioSciences, Inc.</organization>
      <phone>650-649-3530</phone>
      <email>bfinck@coherus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

